A Gynecologic Oncology Group Randomized Phase III Trial of Whole Abdominal Irradiation (WAI) Vs. Cisplatin-ifosfamide and Mesna (CIM) As Post-surgical Therapy in Stage I-IV Carcinosarcoma (CS) of the Uterus

Overview

Journal Gynecol Oncol

Date 2007 Sep 8

PMID 17822748

Citations 62

Authors

Aaron H Wolfson

Mark F Brady

Thomas Rocereto

Robert S Mannel

Yi-Chun Lee

Robert J Futoran

David E Cohn

Olga B Ioffe

Affiliations

Soon will be listed here.

Abstract

Purpose: After initial surgery, there has been no established consensus regarding adjunctive therapy for patients with uterine carcinosarcoma (CS). This study was designed to compare patient outcome following treatment with adjuvant whole abdominal irradiation (WAI) versus (vs.) chemotherapy for patients with this rare group of female pelvic malignancies.

Patients And Methods: Eligible, consenting women with stage I-IV uterine CS, no more than 1 cm postsurgical residuum and/or no extra-abdominal spread had their treatments randomly assigned as either WAI or three cycles of cisplatin (C), ifosfamide (I), and mesna (M).

Results: 232 patients were enrolled, of whom 206 (WAI=105; CIM=101) were deemed eligible. Patient demographics and characteristics were similar between arms. FIGO stage (both arms) was: I=64 (31%); II=26 (13%); III=92 (45%); IV=24 (12%). The estimated crude probability of recurring within 5 years was 58% (WAI) and 52% (CIM). Adjusting for stage and age, the recurrence rate was 21% lower for CIM patients than for WAI patients (relative hazard [RH]=0.789, 95% confidence interval [CI]: (0.530-1.176), p=0.245, 2-tail test). The estimated death rate was 29% lower among the CIM group (RH=0.712, 95% CI: 0.484-1.048, p=0.085, two-tail test).

Conclusion: We did not find a statistically significant advantage in recurrence rate or survival for adjuvant CIM over WAI in patients with uterine CS. However, the observed differences favor the use of combination chemotherapy in future trials.

Citing Articles

Uterine Carcinosarcoma (UCS): A Literature Review and Survival Analysis from a Retrospective Cohort Study.

Maiorano M, Cormio G, Maiorano B, Loizzi V Cancers (Basel). 2024; 16(23).

PMID: 39682097 PMC: 11640543. DOI: 10.3390/cancers16233905.

Guiding adjuvant radiotherapy in stage III endometrial cancer: a prognostic model based on SEER.

Li C, Han Z, Chen L, Du G, Cai R Front Oncol. 2024; 14:1480102.

PMID: 39610926 PMC: 11602650. DOI: 10.3389/fonc.2024.1480102.

Carcinosarcoma of the nasal cavity and paranasal sinuses: Review of the national cancer database.

Harris J, Eide J, Kshirsagar R, Brant J, Palmer J, Adappa N World J Otorhinolaryngol Head Neck Surg. 2023; 9(2):115-122.

PMID: 37383334 PMC: 10296035. DOI: 10.1002/wjo2.82.

Clinico-Pathological Characteristics, Management, and Prognostic Factors of Patients with Uterine Carcinosarcoma: a Retrospective Analysis.

Goyal A, Rajshekar S, Krishnappa S, Rathod P, Reddihalli P, Bafna U Indian J Surg Oncol. 2023; 14(2):466-472.

PMID: 37324314 PMC: 10267038. DOI: 10.1007/s13193-022-01563-1.

Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival.

Gracia M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Polterauer S Cancers (Basel). 2023; 15(5).

PMID: 36900255 PMC: 10001122. DOI: 10.3390/cancers15051463.

References

McCluggage W . Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002; 12(6):687-90. DOI: 10.1136/ijgc-00009577-200211000-00001. View

Gadducci A, Romanini A . Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol. 2002; 22(5):352-7. View

Callister M, Ramondetta L, Jhingran A, Burke T, Eifel P . Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004; 58(3):786-96. DOI: 10.1016/S0360-3016(03)01561-X. View

Brooks S, Zhan M, Cote T, Baquet C . Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004; 93(1):204-8. DOI: 10.1016/j.ygyno.2003.12.029. View

Dusenbery K, Potish R, Judson P . Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol. 2004; 94(1):191-6. DOI: 10.1016/j.ygyno.2004.04.001. View

Omura G, Blessing J, Major F, Lifshitz S, Ehrlich C, Mangan C . A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985; 3(9):1240-5. DOI: 10.1200/JCO.1985.3.9.1240. View

Hornback N, Omura G, Major F . Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 1986; 12(12):2127-30. DOI: 10.1016/0360-3016(86)90011-8. View

Korn E, Dorey F . Applications of crude incidence curves. Stat Med. 1992; 11(6):813-29. DOI: 10.1002/sim.4780110611. View

Major F, Blessing J, Silverberg S, Morrow C, Creasman W, Currie J . Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993; 71(4 Suppl):1702-9. DOI: 10.1002/cncr.2820710440. View

10.

WOLFSON A, Wolfson D, Sittler S, Breton L, Markoe A, Schwade J . A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol. 1994; 52(1):56-62. DOI: 10.1006/gyno.1994.1011. View

11.

Chi D, Mychalczak B, Saigo P, Rescigno J, Brown C . The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997; 65(3):493-8. DOI: 10.1006/gyno.1997.4676. View

12.

Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones M . The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998; 68(1):8-13. DOI: 10.1006/gyno.1997.4901. View

13.

Molpus K, Reed G, BURNETT L, Jones 3rd H . Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors. Eur J Gynaecol Oncol. 1999; 19(6):541-6. View

14.

Chauveinc L, Deniaud E, Plancher C, Sastre X, Amsani F, De La Rochefordiere A . Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments. Gynecol Oncol. 1999; 72(2):232-7. DOI: 10.1006/gyno.1998.5251. View

15.

Knocke T, Weitmann H, Kucera H, Kolbl H, Pokrajac B, Potter R . Results of primary and adjuvant radiotherapy in the treatment of mixed Müllerian tumors of the corpus uteri. Gynecol Oncol. 1999; 73(3):389-95. DOI: 10.1006/gyno.1999.5400. View

16.

Sutton G, Kauderer J, Carson L, Lentz S, Whitney C, Gallion H . Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005; 96(3):630-4. DOI: 10.1016/j.ygyno.2004.11.022. View

17.

Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M . A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005; 97(1):166-70. DOI: 10.1016/j.ygyno.2004.12.006. View

18.

Dusenbery K, Potish R, Argenta P, Judson P . On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol. 2005; 28(3):295-300. DOI: 10.1097/01.coc.0000156919.04133.98. View

19.

Homesley H, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore L . Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(5):526-31. DOI: 10.1200/JCO.2006.06.4907. View

20.

Reed N, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S . Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44(6):808-18. DOI: 10.1016/j.ejca.2008.01.019. View